Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide in nonmetastatic castration-resistant prostate cancer
NCT02003924Phase 3Completed
- Sponsor
- Pfizer
- Start
- Oct 2013
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 32
01
Overview
A Phase 3 trial of enzalutamide in castration-resistant prostate cancer (CRPC), sponsored by Pfizer. Started Oct 2013; status: completed.
02
Drugs
enzalutamide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT02003924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02003924.